TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22230474
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g mushroom powder (control)
Study: 2184513
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg daily)
Study: 9972860
Drug: Trimethaphan (peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethaphan (peripheral nicotinic receptor antagonist)
Study: 7726398
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered at 1 mg/kg lean body mass followed by a 4-hour infusion at 5 mg.kg-1.h-1 during hypothermia (34 degrees C)
Study: 7726398
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered at 1 mg/kg lean body mass followed by a 4-hour infusion at 5 mg.kg-1.h-1 during normothermia (37 degrees C)
Study: 7726398
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg/kg administered as an intravenous bolus during hypothermia (34 degrees C)
Study: 1319523
Drug: Midazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (1 mg) administered before injection of LA
Study: 6719042
Drug: Aspirin (Bayer)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (Bayer) 500 mg
Study: 6719042
Drug: Reumyl (Hässle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reumyl (Hässle) 500 mg
Study: 11840418
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (taxane and platinum compound)
Study: 11840418
Drug: Second-line treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line treatments (not specified)
Study: 2306061
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of ranitidine (75, 150, and 300 mg every 24 hours)
Study: 23837918
Drug: CHOCAF (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOCAF (25 g carbohydrate + 100 mg caffeine)
Study: 8059918
Drug: 28 days
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 28 days of sodium stibogluconate (Pentostam) at 20 mg/kg/day
Study: 8059918
Drug: 40 days
Normalized name: Viibryd 10/20/40 30 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 days of sodium stibogluconate (Pentostam) at 20 mg/kg/day
Study: 3189721
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (after reinstitution of treatment)
Study: 3189721
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (withdrawal)
Study: 29710164
Drug: Ticagrelor (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (90 mg twice daily) + Aspirin (100 mg once daily)
Study: 25271201
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy (3-month yoga course of group classes and home practice)
Study: 21812923
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolic acid (MPA) with standard dose cyclosporine (SD‐CsA)
Study: 16495245
Drug: Telbivudine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 25 mg/day
Study: 16495245
Drug: Telbivudine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 400 mg/day
Study: 16495245
Drug: Telbivudine 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 800 mg/day
Study: 16495245
Drug: Telbivudine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine (all doses)
Study: 12605972
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment schedules (Conventional and Hypofractionated)
Study: 11092290
Drug: NPH human
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH human insulin
Study: 3097726
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg nicotine during stress
Study: 3097726
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg nicotine alone
Study: 22775412
Drug: Atorvastatin lactone
Normalized name: citronellene lactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin lactone
Study: 23247745
Drug: Atorvastatin acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin acid
Study: 20104219
Drug: Long-term low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Long-term low-dose peginterferon alpha-2a (90 microg/week)
Study: 18779512
Drug: CGRP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CGRP infusion (1.5 microg/min)
Study: 16137507
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (250 ml daily, Cabernet Sauvignon)
Study: 8485067
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg bid
Study: 30209126
Drug: Apixaban and
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban and Warfarin
Study: 23702006
Drug: Transfusion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion with pre-storage leuko-depleted RBC suspended in saline-adenine-glucose and mannitol (SAGM) at haemoglobin level (Hb) of 7 g/dl
Study: 23702006
Drug: Transfusion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion with pre-storage leuko-depleted RBC suspended in saline-adenine-glucose and mannitol (SAGM) at haemoglobin level (Hb) of 9 g/dl
Study: 15167303
Drug: High-dose (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (80 mg isoflavones + 500 mg calcium)
Study: 15167303
Drug: Mid-dose (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-dose (40 mg isoflavones + 500 mg calcium)
Study: 15844675
Drug: Cognitive-behavioral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral group therapy (CBT)
Study: 11874640
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with no formal psychosocial intervention (Control)
Study: 8690170
Drug: Hypoglycaemia (2.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemia (2.9 mmol/l) for 2 hours during hypo week
Study: 8690170
Drug: Euglycaemia (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycaemia (5 mmol/l) for 2 hours during control week
Study: 2543203
Drug: Typical Western
Normalized name: Western Horsetail Top
DrugBank: Equisetum arvense top (DB14349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical Western diet (40% of total calories from fat, 400 mg cholesterol/d, 12 g dietary fiber/d, P:S of 0.5)
Study: 8299660
Drug: Terbutaline 5
Normalized name: terbutaline 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 5 mg
Study: 9598014
Drug: 5% glycolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glycolic acid cream
Study: 22256334
Drug: 62% ethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 62% ethyl alcohol in emollient gel applied by male partners each morning and before and after sexual intercourse
Study: 16584059
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg FA
Study: 16584059
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg FA
Study: 17087779
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg FA
Study: 24793176
Drug: Monthly intervention
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly intervention group (GIM): instructions on fall prevention and healthy exercises with monthly refresher sessions.
Study: 22537767
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (2 mg/day) + MPA (5mg/day)
Study: 22537767
Drug: Estradiol-only therapy
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol-only therapy
Study: 1830636
Drug: All hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All hormone regimens
Study: 20666584
Drug: tgAAC09 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tgAAC09 (2 doses)
Study: 10341854
Drug: Interleukin-2 treatment
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-2 treatment
Study: 21204686
Drug: Brief Direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Direct Treatment Intervention (BDTI)
Study: 9374124
Drug: 0 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/d fish oil (control)
Study: 1347210
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Breathing Retraining and Cognitive Restructuring with Self-Exposure
Study: 1347210
Drug: Further treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further treatment during follow-up period
Study: 1347210
Drug: Demographic variables,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demographic variables, pre- and posttest scores, medication use
Study: 23732372
Drug: Tuberil® (weight-loss
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuberil® (weight-loss supplement derived from potato)
Study: 20163990
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta and high-dose daclizumab (2 mg/kg every 2 weeks)
Study: 20163990
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta and low-dose daclizumab (1 mg/kg every 4 weeks)
Study: 11938858
Drug: Salvia miltiorrhiza
Normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia miltiorrhiza compound injection (SMCI) 200 mg/kg intravenously before operation and at rewarming
Study: 1302811
Drug: Isoconazole nitrate
Normalized name: isoconazole nitrate
DrugBank: Isoconazole (DB08943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoconazole nitrate (1% cream, Travogen)
Study: 1302811
Drug: Clotrimazole (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (1% cream, Canestan)
Study: 3891821
Drug: Diltiazem (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (high dose 240 mg/day)
Study: 30741790
Drug: PLLA injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLLA injections
Study: 7368149
Drug: Saline injections
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injections (control group)
Study: 27904000
Drug: Medium chain
Normalized name: Medium chain triglyceride
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium chain triglycerides oil (6 g/d for 8 weeks)
Study: 26976420
Drug: High fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fluid intake along with antimyeloma therapy
Study: 26976420
Drug: High-cutoff hemodialysis
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-cutoff hemodialysis membranes in combination with antimyeloma therapy
Study: 26976420
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy with autologous stem cell transplantation (with melphalan 100 mg/m(2) to 140 mg/m(2))
Study: 14533654
Drug: Oral ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ingestion of biogenic amines (specific types not detailed)
Study: 11739444
Drug: Acipimox (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (500 mg)
Study: 7851578
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (LA; Lupron) 0.1 mg SC daily for 3 months
Study: 7851578
Drug: Danazol (Danocrine)
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol (Danocrine) 800 mg orally daily for 3 months
Study: 6108895
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg tiotidine
Study: 6108895
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tiotidine
Study: 31950152
Drug: Novel medications
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel medications co-administered with alcohol
Study: 28646807
Drug: Kaltenborn‐Evjenth orthopedic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaltenborn‐Evjenth orthopedic manual therapy (KEOMT) combined with cryotherapy (KEOMT‐C)
Study: 28646807
Drug: Kaltenborn‐Evjenth orthopedic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaltenborn‐Evjenth orthopedic manual therapy (KEOMT) combined with Kinesio taping (KEOMT‐K)
Study: 22402257
Drug: EE 20
Normalized name: AcidFree 200mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 20 mcg/drsp 3 mg in a 21/7-day regimen
Study: 19671292
Drug: Multimodal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal group (Group M) with intravenous fentanyl and atracurium, inhalation of nitrous oxide/oxygen (50%:50%) and sevoflurane (5%)
Study: 19671292
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group C) with inhalation of nitrous oxide/oxygen (50%:50%) and sevoflurane (5%)
Study: 17722318
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg oral misoprostol
Study: 7030652
Drug: Flunisolide aerosol
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide aerosol 0.5 mg (two inhalations) twice daily
Study: 25819701
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy based self-help introduced by CDAT workers
Study: 23665671
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml normal saline with 1:200,000 epinephrine per tonsil (Group 1)
Study: 23665671
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml 1% lidocaine with 1:200,000 epinephrine per tonsil (Group 2)
Study: 23665671
Drug: 8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ml normal saline with 1:200,000 epinephrine per tonsil (Group 3)
Study: 21131668
Drug: 17.4 mg/24
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17.4 mg/24 h rivastigmine patch
Study: 19484917
Drug: rivastigmine capsule
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: rivastigmine capsule (3 to 6 mg twice-daily)
Study: 6377997
Drug: Daily streptomycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily streptomycin, isoniazid, rifampin, and pyrazinamide for 12 months
Study: 6377997
Drug: Selective chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective chemotherapy (antituberculosis chemotherapy not started until disease confirmed active)
Study: 30325658
Drug: GH antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GH antagonist treatment
Study: 10655953
Drug: Inulin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (10 g daily)
Study: 1987105
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 0.5% ophthalmic solution, 1 drop twice daily for 14 days
Study: 418431
Drug: Pimozide tablets
Normalized name: Pimozide Tablets
DrugBank: Pimozide (DB01100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimozide tablets
Study: 394794
Drug: Fluphenazine decanoate
Normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluphenazine decanoate injections
Study: 31831042
Drug: Preoperative concurrent
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative concurrent chemoradiotherapy (n=104)
Study: 19222614
Drug: Levodopa therapy
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa therapy alone
Study: 17406754
Drug: IFN 3
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN 3 MU daily + ribavirin 1.0‐1.2 g daily for 12 weeks followed by IFN 3 MU thrice weekly + ribavirin 1.0‐1.2 g daily for 48 weeks (IFN QD)
Study: 12793140
Drug: Captopril (capoten)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (capoten) 25‐75 mg/day for 4 weeks
Study: 12793140
Drug: Benazepril (lotensin)
Normalized name: benazepril Oral Tablet [Lotensin]
DrugBank: Benazepril (DB00542)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benazepril (lotensin) 5‐30 mg/day for 24 weeks
Study: 7778148
Drug: Paracetamol given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol given 2 h after quinine (n = 7)
Study: 7778148
Drug: Paracetamol given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol given 2 h before quinine (n = 7)
Study: 2212378
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of Fluosol-DA 20%
Study: 31927748
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous methylprednisolone (4.5 g cumulative dose during 12 weekly infusions)
Study: 18674978
Drug: Individualized pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized pressure ulcer education and monthly structured telephone follow-up (n=20)
Study: 18674978
Drug: Monthly mail
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly mail or telephone follow-up without educational content (n=11)
Study: 19200542
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg/day
Study: 10403866
Drug: 1.2 ml
Normalized name: Mozobil 24 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 ml 0.5% bupivacaine (6 mg)
Study: 10403866
Drug: 3.4 ml
Normalized name: ALCOHOL 43.4 mL in 70 mL TOPICAL GEL [Dr. HANDs Gel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 ml 0.18% hypobaric bupivacaine (6.1 mg)
Study: 2333740
Drug: Follow-up formula
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up formula with 1.5 g protein/dl (2.0 g/kg/d)
Study: 2333740
Drug: Follow-up formula
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up formula with 2.2 g protein/dl (3.0 g/kg/d)
Study: 2333740
Drug: Follow-up formula
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up formula with 2.9 g protein/dl (3.7 g/kg/d)
Study: 2333740
Drug: Formula only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula only (15 g/dl)
Study: 6999291
Drug: Probucol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (1000 mg/day)
Study: 23642941
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg)
Study: 19076108
Drug: Paracetamol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol + Pregabalin + Dexamethasone
Study: 19076108
Drug: Paracetamol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol + Pregabalin
Study: 19076108
Drug: Paracetamol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol + Placebo
Study: 3898440
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 gram preoperative dose)
Study: 3898440
Drug: Cefazolin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (three 1 gram parenteral doses over a 16 hour period)
Study: 24641678
Drug: levodopa 0.76
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa 0.76 mg/kg with 25% carbidopa
Study: 24641678
Drug: levodopa 0.51
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa 0.51 mg/kg with 25% carbidopa
Study: 18823469
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ketorolac i.v. after induction of anaesthesia
Study: 18823469
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg etoricoxib orally as premedication
Study: 12460706
Drug: Hydrochlorthiazide (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorthiazide (12.5 mg/day)
Study: 10783990
Drug: New developments
Approvals — FDA: no, EMA: no, PMDA: no
Description: New developments in chemotherapy
Study: 1345755
Drug: Lowest zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lowest zidovudine dose alone (regimen 6)
Study: 1345755
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with zidovudine and ddC at the doses tested
Study: 1345755
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose of 150 mg of zidovudine
Study: 6735963
Drug: Oltipraz administered
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz administered under fasting conditions (25 mg/kg)
Study: 6735963
Drug: Oltipraz administered
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz administered with a low fat meal (less than 5% fat)
Study: 6735963
Drug: Oltipraz administered
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz administered with a high fat meal (24% fat)
Study: 8679366
Drug: Morphine 0.2
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.2 mg
Study: 21644105
Drug: Fentanyl 25
Normalized name: FENTANYL 25MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 25 µg